Silkworms as Bio-factories for Medical Advancements

Silkworms have spent thousands of years doing one thing extraordinarily well – spinning silk. But today, these tiny insects are being put to work in an entirely different way. Advances in genetic engineering have transformed Bombyx mori, the domestic silkworm, from a textile producer into a powerful biological manufacturing platform. Scientists are now using silkworms to produce human proteins, vaccine components, therapeutic enzymes, and antibody drugs – turning sericulture into a front-line contributor to modern medicine.

What is a bio-factory?
Why silkworms outperform conventional production systems
How the genetic engineering process works
The baculovirus expression system
Transgenic silkworm technology
Human collagen from silkworm cocoons
Vaccine production using silkworm bio-factories
Therapeutic proteins and growth factors
Advantages, challenges, and the road ahead

What is a bio-factory?

A bio-factory is a living organism that has been genetically modified to produce specific proteins or other valuable compounds. Rather than building a chemical plant to synthesize a molecule from scratch, scientists reprogram a biological host – such as a bacterium, yeast, or insect – to manufacture it naturally through its own cellular machinery. Silkworms are among the most effective hosts for this purpose. Research published in Applied Microbiology and Biotechnology explains that Bombyx mori has been used for silk production for centuries and has more recently emerged as a potent protein production bioreactor.

What makes silkworms particularly suited for this role? The answer lies in their silk glands. According to a study published in Frontiers in Nutrition, the silk gland of a silkworm weighing approximately 2 grams can produce up to 500 mg of silk proteins – roughly 25% of the larval dry weight. This capacity for producing large quantities of protein in a compact biological system is exactly what biotechnologists need.

Why silkworms outperform conventional production systems

Traditional pharmaceutical manufacturing relies heavily on mammalian cell cultures or bacterial systems like Escherichia coli. These approaches are effective but come with serious drawbacks – high infrastructure costs, specialized bioreactor equipment, expensive growth media, and complex purification procedures.

Silkworms offer a compelling alternative. A comprehensive review from Shizuoka University, published in Protein Expression and Purification, notes that unlike E. coli expression systems, silkworms can produce recombinant proteins with the added benefits of post-translational modification, easy scalability, and low production costs – without requiring bioreactors, specialized facilities, or expensive media. Silkworms only need a temperature-controlled chamber and mulberry leaves. The gene of interest can also be transfected into silkworms with results obtainable within about one week, which is faster than insect cell culture systems that require multiple culturing steps to increase cell density.

There is also a biosafety advantage. The silkworm baculovirus system uses Bombyx mori nucleopolyhedrovirus (BmNPV), which is highly host-specific and presents fewer safety concerns compared to broader-spectrum viruses used in other expression systems. ScienceDirect’s overview of baculovirus expression systems highlights that BmNPV’s specificity, combined with higher protein solubility and existing sericulture infrastructure across Asia, makes the silkworm system particularly attractive for scale-up.

How the genetic engineering process works

There are two main methods used to convert silkworms into bio-factories: the baculovirus expression system and transgenic silkworm technology.

The baculovirus expression system

In this approach, scientists insert the gene for a desired protein into a modified baculovirus. The virus is then used to infect silkworm larvae or pupae. Once inside the silkworm, the virus directs the insect’s cellular machinery to produce the target protein in large quantities – particularly in the hemolymph (insect blood), from which the protein can be extracted and purified. An MDPI review on baculovirus expression vector systems describes this as a flexible, rapid, and cost-effective vaccine platform with high safety and scalability.

Transgenic silkworm technology

In this approach, the target gene is permanently inserted into the silkworm’s own chromosome using techniques such as piggyBac transposon vectors. The modified silkworm then expresses the desired protein as part of its normal biology – typically secreting it directly into the silk cocoon. Japanese biotechnology firm IBL, a pioneer in this field, explains that this system is especially suitable for producing high molecular weight proteins made up of multiple subunits – a class of molecules that other expression systems often struggle with.

Human collagen from silkworm cocoons

One of the most significant early achievements in silkworm bio-factory research was the production of human collagen – a structural protein critical to skin, connective tissue, and wound healing, and widely used in cosmetic surgery and medical treatments.

A landmark 2003 study published in Nature Biotechnology by Tomita et al. demonstrated the generation of transgenic silkworms that produced cocoons containing recombinant human type III procollagen. The researchers inserted a human collagen gene fused to the fibroin light-chain promoter, directing the protein into the silk gland so that it was secreted directly into the cocoon. The fusion proteins were successfully purified and confirmed by multiple analytical tests.

This research had immediate commercial implications. IBL Japan subsequently commercialized human type I collagen α1 chain produced by transgenic silkworms under the name “Neosilk-Human Collagen I.” Because this collagen is human-derived, it carries minimal risk of allergic reactions compared to collagen sourced from animals – making it a safer ingredient for use in cosmetics and medical biomaterials. Beyond collagen, a ScienceDirect study on silk-based biomaterials reports that transgenic silkworms have also been used as bioreactors to express human serum albumin, human acid fibroblast growth factor, and antibodies alongside their native silk proteins.

Vaccine production using silkworm bio-factories

Vaccine development is one of the most high-impact applications of silkworm bio-factories. A key tool here is the production of virus-like particles (VLPs) – structures that mimic the outer shell of a virus without containing any viral genetic material. Because VLPs cannot replicate, they pose no infection risk, but their structure triggers strong immune responses, making them highly effective vaccine candidates.

Research published in PLOS ONE demonstrated that the BmNPV-silkworm expression system provides enhanced expression levels and significantly lower costs compared to conventional cell-line-based systems, giving it strong potential for industrial-scale VLP vaccine production. The study successfully produced rotavirus-like particles containing three different viral coat proteins simultaneously.

Other vaccine targets have followed. A study in Vaccine reported that silkworm pupae were used to produce approximately 4.9 mg of purified norovirus VP1 protein from just five silkworm pupae, with the protein self-assembling into VLPs approximately 40 nm in diameter. These VLPs were confirmed to have strong immunogenic properties, making them promising candidates for a norovirus vaccine. VLP-based vaccines for human papillomavirus (HPV) and hepatitis B, produced using related insect-cell baculovirus systems, are already commercially approved – establishing a proven regulatory pathway for silkworm-derived products.

The Springer Nature study on silkworm expression systems also documents that TORAY Industries in Japan used silkworms to produce two interferon-based veterinary drugs – Intercat for feline calicivirus and Interdog for canine atopic dermatitis – which were the first commercially approved antiviral drugs produced using this platform. These represent the proof-of-concept that has since driven wider pharmaceutical interest in the technology.

Therapeutic proteins and growth factors

Beyond vaccines and collagen, silkworm bio-factories are being explored for a broader class of therapeutically important proteins. A study published in PMC on transgenic silkworm production of human epidermal growth factor (hEGF) demonstrated that the protein was successfully expressed in cocoon shells of transgenic silkworms. When researchers knocked out an endogenous silk protein gene (P25), hEGF production increased by approximately 2.2-fold – demonstrating that yield optimization strategies can significantly improve output.

Researchers are also producing platelet-derived growth factor (PDGF-BB) in transgenic silkworms. A review in Biotechnology and Bioengineering notes that transgenic modification of Bombyx mori has led to the production of therapeutic proteins and biomolecules in reasonable quantities at affordable costs for tissue engineering and other medical applications, including growth factors, fluorescent proteins, and high-performance protein fibers. PDGF is a major therapeutic protein in high clinical demand, particularly for wound healing and tissue regeneration – areas where silkworm-derived supply could fill critical gaps.

Monoclonal antibodies are another target. Research from OMICS International describes how mouse IgG monoclonal antibodies were produced using the silkworm sericin expression system. The antibody was purified from cocoons and showed antigen-binding affinity nearly identical to that of the native antibody – a critical quality benchmark for pharmaceutical use. IBL Japan also produces stable, high-quality monoclonal antibodies using transgenic silkworms for use in ELISA diagnostic kits.

Advantages, challenges, and the road ahead

The case for silkworm bio-factories is strong. They are cost-effective, scalable without specialized equipment, capable of performing the complex post-translational modifications that bacterial systems cannot, and supported by existing sericulture infrastructure across India, China, Japan, and other Asian countries. KAICO Ltd., a Japan-based biotechnology startup, has advanced silkworm-based biologics to Phase I vaccine trials, demonstrating that regulatory hurdles are being actively navigated.

Challenges do remain. Protein yields from transgenic silkworms, while improving, are still often lower than those achievable in mammalian cell cultures. Regulatory pathways for human-grade biologics produced in insects are more complex than for veterinary applications. Post-translational glycosylation patterns in silkworms also differ from those in human cells, which can affect how certain proteins function in the body. Ongoing research into gene knockout strategies, codon optimization, and chaperone-assisted expression is steadily addressing these limitations.

The global market for recombinant proteins and biologics runs into hundreds of billions of dollars annually. As highlighted in NuFoods Spectrum, silkworms represent a low-capital, sustainable biomanufacturing platform that greatly lowers cost and environmental impact compared to conventional mammalian or insect cell cultures – a compelling proposition for emerging economies looking to build domestic pharmaceutical manufacturing capacity. Countries with deep sericulture traditions are already investing in the research infrastructure needed to scale bio-factory operations, turning an ancient agricultural industry into a biotechnology asset.

What do you think? As silkworm bio-factories move closer to producing approved human biologics, should countries with established sericulture industries – like India and China – be prioritizing investment in this technology as part of their pharmaceutical self-sufficiency strategies? And with silkworm-derived human collagen already in cosmetics, how soon do you think fully silkworm-produced therapeutics will reach clinical use at scale?

How useful was this post?

Click on a star to rate it!

Average rating 0 / 5. Vote count: 0

No votes so far! Be the first to rate this post.

References

PDF 📄

Table of Contents

What is a bio-factory? 🔗

Why silkworms outperform conventional production systems 🔗

How the genetic engineering process works 🔗

The baculovirus expression system 🔗

Transgenic silkworm technology 🔗

Human collagen from silkworm cocoons 🔗

Vaccine production using silkworm bio-factories 🔗

Therapeutic proteins and growth factors 🔗

Advantages, challenges, and the road ahead 🔗